$ARDX
ARDELYX, INC. Stock $ardx

$ardx Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000162828023026569 Filed on August 02, 2023

Income Statement

Concept	2023 Q3	2023 Q2
Revenue	$56.39M	$22.33M
YoY Change	1030.99%	784.13%
Cost Of Revenue	$7.692M	$3.489M
YoY Change	950.82%	2428.26%
Gross Profit	$48.70M	$18.84M
YoY Change	1044.78%	689.11%
Gross Profit Margin	86.36%	84.38%
Selling, General & Admin	$32.66M	$27.19M
YoY Change	74.98%	44.13%
% of Gross Profit	67.07%	144.27%
Research & Development	$8.637M	$8.282M
YoY Change	15.67%	-14.98%
% of Gross Profit	17.74%	43.95%
Depreciation & Amortization	$290.0K	$639.0K
YoY Change	-53.82%	265.14%
% of Gross Profit	0.6%	3.39%
Operating Expenses	$41.30M	$35.47M
YoY Change	58.04%	24.0%
Operating Profit	$7.398M	-$16.62M
YoY Change	-133.81%	-36.59%
Interest Expense	$1.107M	-$1.075M
YoY Change	24.94%	-236.59%
% of Operating Profit	14.96%
Other Income/Expense, Net	$1.460M	$578.0K
YoY Change	107.39%	725.71%
Pretax Income	$6.829M	-$17.12M
YoY Change	-129.83%	-36.43%
Income Tax	$200.0K	$0.00
% Of Pretax Income	2.93%
Net Earnings	$6.629M	-$17.12M
YoY Change	-128.96%	-36.44%
Net Earnings / Revenue	11.76%	-76.66%
Basic Earnings Per Share	$0.03	-$0.08
Diluted Earnings Per Share	$0.03	-$0.08
COMMON SHARES
Basic Shares Outstanding	217.9M shares	214.5M shares
Diluted Shares Outstanding	227.9M shares	215.0M shares

Balance Sheet

Concept	2023 Q3	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$165.1M	$127.6M
YoY Change	82.16%	57.48%
Cash & Equivalents	$33.77M	$28.66M
Short-Term Investments	$131.3M	$97.52M
Other Short-Term Assets	$24.30M	$17.81M
YoY Change	6.61%	-22.36%
Inventory	$47.50M	$7.617M
Prepaid Expenses
Receivables	$43.26M	$9.109M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$241.2M	$162.1M
YoY Change	101.22%	42.08%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.116M	$8.117M
YoY Change	-13.76%	426.74%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.550M	$40.97M
YoY Change	-88.36%	734.72%
Total Long-Term Assets	$48.16M	$49.09M
YoY Change	94.23%	180.44%
TOTAL ASSETS
Total Short-Term Assets	$241.2M	$162.1M
Total Long-Term Assets	$48.16M	$49.09M
Total Assets	$289.4M	$211.2M
YoY Change	100.02%	60.48%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$7.736M	$5.294M
YoY Change	148.51%	23.29%
Accrued Expenses	$31.70M	$23.38M
YoY Change	73.28%	29.68%
Deferred Revenue	$4.072M	$5.959M
YoY Change	1.72%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$27.05M
YoY Change	-100.0%	2.57%
Total Short-Term Liabilities	$43.53M	$61.69M
YoY Change	-16.21%	26.67%
LONG-TERM LIABILITIES
Long-Term Debt	$27.20M	$0.00
YoY Change
Other Long-Term Liabilities	$170.0K	$26.35M
YoY Change	-99.34%	-11.77%
Total Long-Term Liabilities	$170.0K	$26.35M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$43.53M	$61.69M
Total Long-Term Liabilities	$170.0K	$26.35M
Total Liabilities	$98.22M	$88.04M
YoY Change	26.23%	12.06%
SHAREHOLDERS EQUITY
Retained Earnings	-$817.4M	-$824.0M
YoY Change	3.36%	7.31%
Common Stock	$1.009B	$947.4M
YoY Change	17.6%	15.38%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$191.2M	$123.2M
YoY Change
Total Liabilities & Shareholders Equity	$289.4M	$211.2M
YoY Change	100.02%	60.48%

Cashflow Statement

Concept	2023 Q3	2023 Q2
OPERATING ACTIVITIES
Net Income	$6.629M	-$17.12M
YoY Change	-128.96%	-36.44%
Depreciation, Depletion And Amortization	$290.0K	$639.0K
YoY Change	-53.82%	265.14%
Cash From Operating Activities	-$21.47M	-$14.74M
YoY Change	-15.56%	-52.89%
INVESTING ACTIVITIES
Capital Expenditures	$190.0K	$93.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$32.50M	-$59.11M
YoY Change	3806.25%	-482.02%
Cash From Investing Activities	-$32.70M	-$59.21M
YoY Change	3830.29%	-482.62%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	57.88M	11.52M
YoY Change	67.87%	-47.99%
NET CHANGE
Cash From Operating Activities	-21.47M	-14.74M
Cash From Investing Activities	-32.70M	-59.21M
Cash From Financing Activities	57.88M	11.52M
Net Change In Cash	3.710M	-62.43M
YoY Change	-54.87%	-1086.08%
FREE CASH FLOW
Cash From Operating Activities	-$21.47M	-$14.74M
Capital Expenditures	$190.0K	$93.00K
Free Cash Flow	-$21.66M	-$14.83M
YoY Change	-14.81%	-52.59%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q2	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	9238000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	9025000	usd
CY2023Q2	ardx	Deferred Royalty Obligation Noncurrent DeferredRoyaltyObligationNoncurrent	13191000	usd
CY2022Q4	ardx	Deferred Royalty Obligation Noncurrent DeferredRoyaltyObligationNoncurrent	11254000	usd
CY2023Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	172000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	usd
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	22333000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2526000	usd
CY2023Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3489000	usd
CY2022Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	138000	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8282000	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9741000	usd
CY2023Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	27186000	usd
CY2022Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	18862000	usd
CY2023Q2	us-gaap	Costs And Expenses CostsAndExpenses	35468000	usd
CY2022Q2	us-gaap	Costs And Expenses CostsAndExpenses	28603000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-16624000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-26215000	usd
CY2023Q2	us-gaap	Interest Expense InterestExpense	1075000	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	777000	usd
CY2023Q2	us-gaap	Amortization Of Advance Royalty AmortizationOfAdvanceRoyalty	968000	usd
CY2022Q2	us-gaap	Amortization Of Advance Royalty AmortizationOfAdvanceRoyalty	10000	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1546000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-26938000	usd
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.21
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.21
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	214951127	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	145544372	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	211009029	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	138279945	shares
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-17121000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-26938000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-190000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-21000	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-17311000	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-26959000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	125421000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	337000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	149000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	11366000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3199000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-190000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-17121000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	123161000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	98329000	usd
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	138000	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	337000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	211000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	62085000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6111000	usd
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-156000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-43894000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	123161000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	64190000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	12557000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3254000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-21000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	82617000	usd
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	83000	usd
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0	usd
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	853000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	2090000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	151000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	521000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-136000	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	1268000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	107000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-68984000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	17806000	usd
	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	0	usd
	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	26971000	usd
	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	0	usd
	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	33038000	usd
	ardx	Proceeds From Sale Of Future Royalties Net Of Issuance Costs ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts	0	usd
	ardx	Proceeds From Sale Of Future Royalties Net Of Issuance Costs ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts	9581000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	62085000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	18478000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	349000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	83000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-66082000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	96140000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	72428000	usd
	us-gaap	Interest Paid Net InterestPaidNet	1757000	usd
	us-gaap	Interest Paid Net InterestPaidNet	1360000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	19000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	6000	usd
	us-gaap	Stock Issued1 StockIssued1	337000	usd
	us-gaap	Stock Issued1 StockIssued1	0	usd
	ardx	Derivative Issued DerivativeIssued	0	usd
	ardx	Derivative Issued DerivativeIssued	375000	usd
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the amounts reported in the financial statements and accompanying notes thereto. On an ongoing basis, management evaluates its estimates, including those related to recognition of revenue, clinical trial accruals, contract manufacturing accruals, utilization of inventory, fair value of assets and liabilities, income taxes and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could materially differ from those estimates.</span></div>
CY2023Q2	us-gaap	Investments And Cash InvestmentsAndCash	127600000	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-824000000	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	30058000	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	30058000	usd
CY2023Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	97731000	usd
CY2023Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	21000	usd
CY2023Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	231000	usd
CY2023Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	97521000	usd
CY2023Q2	ardx	Investments And Cash Amortized Cost InvestmentsAndCashAmortizedCost	127789000	usd
CY2023Q2	ardx	Cash Cash Equivalents And Investments Gross Unrealized Gains CashCashEquivalentsAndInvestmentsGrossUnrealizedGains	21000	usd
CY2023Q2	ardx	Cash Cash Equivalents And Investments Gross Unrealized Losses CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses	231000	usd
CY2023Q2	us-gaap	Investments And Cash InvestmentsAndCash	127579000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	96140000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	96140000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	27823000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	6000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	60000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	27769000	usd
CY2022Q4	ardx	Investments And Cash Amortized Cost InvestmentsAndCashAmortizedCost	123963000	usd
CY2022Q4	ardx	Cash Cash Equivalents And Investments Gross Unrealized Gains CashCashEquivalentsAndInvestmentsGrossUnrealizedGains	6000	usd
CY2022Q4	ardx	Cash Cash Equivalents And Investments Gross Unrealized Losses CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses	60000	usd
CY2022Q4	us-gaap	Investments And Cash InvestmentsAndCash	123909000	usd
	ardx	Available For Sale Securities Debt Securities Current Contractual Maturities Maximum AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum	P1Y
CY2022	ardx	Available For Sale Securities Debt Securities Current Contractual Maturities Maximum AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum	P1Y
CY2023Q2	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	0	investment
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	0	investment
CY2022Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2023Q2	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2023Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	22783000	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	22299000	usd
CY2023Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	23527000	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	5324000	usd
CY2023Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1602000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	723000	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	47912000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	28346000	usd
CY2023Q2	us-gaap	Inventory Gross InventoryGross	7617000	usd
CY2022Q4	us-gaap	Inventory Gross InventoryGross	3282000	usd
CY2023Q2	us-gaap	Inventory Noncurrent InventoryNoncurrent	40295000	usd
CY2022Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	25064000	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	47912000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	28346000	usd
CY2023Q2	ardx	Prepaid Commercial Manufacturing Current PrepaidCommercialManufacturingCurrent	13200000	usd
CY2022Q4	ardx	Prepaid Commercial Manufacturing Current PrepaidCommercialManufacturingCurrent	13600000	usd
CY2022Q4	ardx	Contract With Customer Gross To Net Sales Accruals ContractWithCustomerGrossToNetSalesAccruals	2844000	usd
	ardx	Contract With Customer Gross To Net Sales Provisions ContractWithCustomerGrossToNetSalesProvisions	12974000	usd
	ardx	Contract With Customer Gross To Credits Or Deductions Issued ContractWithCustomerGrossToCreditsOrDeductionsIssued	-9971000	usd
CY2023Q2	ardx	Contract With Customer Gross To Net Sales Accruals ContractWithCustomerGrossToNetSalesAccruals	5847000	usd
CY2023Q2	us-gaap	Amortization Of Advance Royalty AmortizationOfAdvanceRoyalty	1000000	usd
	us-gaap	Amortization Of Advance Royalty AmortizationOfAdvanceRoyalty	1900000	usd
	us-gaap	Amortization Of Advance Royalty AmortizationOfAdvanceRoyalty	0	usd
CY2022Q2	us-gaap	Amortization Of Advance Royalty AmortizationOfAdvanceRoyalty	0	usd
	us-gaap	Proceeds From Royalties Received ProceedsFromRoyaltiesReceived	0	usd
CY2023Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	28861000	usd
CY2023Q2	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	1280000	usd
CY2023Q2	us-gaap	Debt Instrument Fee Amount DebtInstrumentFeeAmount	529000	usd
CY2023Q2	us-gaap	Long Term Debt LongTermDebt	27052000	usd
CY2023Q2	us-gaap	Loans Payable Current LoansPayableCurrent	27052000	usd
CY2023Q2	us-gaap	Long Term Loans Payable LongTermLoansPayable	0	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7053000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	9295000	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4105000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3894000	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3752000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5855000	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	7857000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	9749000	usd
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y4M24D
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.068
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.068
CY2023Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	1064000	usd
CY2022Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	1064000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	2128000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	2128000	usd
CY2023Q2	us-gaap	Operating Lease Payments OperatingLeasePayments	1100000	usd
CY2022Q2	us-gaap	Operating Lease Payments OperatingLeasePayments	1064000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	2198000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	2122000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	2242000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	4589000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1321000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	252000	usd
CY2023Q2	ardx	Lessee Operating Lease Liability To Be Paid After Year Three LesseeOperatingLeaseLiabilityToBePaidAfterYearThree	0	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	8404000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	547000	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	7857000	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4105000	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3752000	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3199000	usd
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3193000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6111000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6824000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	13963000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.83
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	7331000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.92
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	99000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.12
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	121000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	4.87
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	21074000	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.18
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	10269000	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	5.63
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-17121000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-26938000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-43894000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-55009000	usd
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	214951000	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	214951000	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	145544000	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	145544000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	211009000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	211009000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	138280000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	138280000	shares
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.08
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.19
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.21
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.21
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.40
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.40
CY2023Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	23945000	shares
CY2022Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16819000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	23471000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	17321000	shares
CY2023Q2	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	0	usd
CY2023Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001628280-23-026569-index-headers.html	Edgar Link	pending
0001628280-23-026569-index.html	Edgar Link	pending
0001628280-23-026569.txt	Edgar Link	pending
0001628280-23-026569-xbrl.zip	Edgar Link	pending
ardx-20230630.htm	Edgar Link	pending
ardx-20230630.xsd	Edgar Link	pending
ardx-20230630xex311.htm	Edgar Link	pending
ardx-20230630xex312.htm	Edgar Link	pending
ardx-20230630xex321.htm	Edgar Link	pending
ardx-20230630_g1.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
ardx-20230630_cal.xml	Edgar Link	unprocessable
ardx-20230630_def.xml	Edgar Link	unprocessable
ardx-20230630_lab.xml	Edgar Link	unprocessable
ardx-20230630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
ardx-20230630_htm.xml	Edgar Link	completed
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ARDX
ARDELYX, INC. Stock $ardx

2023 Q3 Form 10-Q Financial Statement

#000162828023026569 Filed on August 02, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ARDX ARDELYX, INC. Stock $ardx

2023 Q3 Form 10-Q Financial Statement

#000162828023026569 Filed on August 02, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ARDX
ARDELYX, INC. Stock $ardx